Severe visual loss secondary to central serous chorioretinopathy following prolonged immune suppression with oral prednisolone by Harikrishnan, A et al.
Severe visual loss secondary to
central serous chorioretinopathy
following prolonged immune
suppression with oral prednisolone
A Harikrishnan1 ￿ K Anderson2 ￿ SP a t r a 3
1University of Bristol Medical School, UK
2The Richard Bright Renal Unit, Southmead Hospital, UK
3Whipps Cross University Hospital, London, UK
Correspondence to: Sudeshna Patra. E-mail: eshnac@yahoo.co.uk
Central serous chorioretinopathy (CSCR) is often
self-limiting but can have serious ocular compli-
cations. We present a case of severe visual loss sec-
ondary to chronic CSCR in a renal transplant
patient on long-term corticosteriods.
Case history
A50-year-oldmanpresentedtotheeyeclinicwitha
12-month history of a gradual loss of vision in the
right eye. He had no signiﬁcant past ocular history
but had been diagnosed at the age of 10 years with
Henoch-Schonlein nephritis. He had a renal trans-
plantin1997andhadbeentakingoralprednisolone
for the past 12 years as part of his immunosuppres-
sion regime. He also suffered from hyperparathyr-
oidism and had recently been diagnosed with
type 2 diabetes. At the time of presentation his
medication included immunosuppression with
cyclosporin 50 mg twice daily, azothiaprine
100 mg and prednisolone 7.5 mg. He was also on
candesartan, atenolol, furosemide, simvastatin,
alfacalcidol, darbepoetin alfa and cinacalcet.
On examination his visual acuities were 2/60 in
the right eye and 6/4 in the left eye. The anterior
segments, intraocular pressures and crystalline
lenses were normal in both eyes. A dilated
ophthalmic examination revealed diffuse non-
speciﬁc retinal pigment epithelial (RPE) changes
in both eyes. Therewere no clinical signs of subret-
inal ﬂuid or neurosensory or pigment epithelial
retinal detachments in either eye although the
ocular coherence tomogram (OCT) detected
shallow extrafoveal subretinal ﬂuid in the left
eye. The OCT, fundus autoﬂuorescence (FA) and
fundus ﬂuorescein angiogram (FFA) ﬁndings are
shown in Figure 1. The optic discs were healthy.
A diagnosis of steroid-induced chronic central
serous retinopathy was made. The right eye had
inactive end-stage disease. However, the presence
of shallow subretinal ﬂuid in the left eye indicated
residual disease activity in this eye. If left untreated
there remained the threat of foveal involvement
and loss of vision. After discussion with the treat-
ing renal physician and the patient it was decided
to reduce the oral prednisolone while jointly moni-
toring both the renal function and the ophthalmic
condition. His oral prednisolone has been gradu-
ally reduced over three months from 7.5 mg to
2 mg. Both his transplant function and ocular
status remain stable on this reduced dose.
Discussion
Central serous chorioretinopathy (CSCR) is an
ocular disease that typically presents with
blurred vision and a neurosensory detachment
of the central macula.
1 While most cases are self-
limiting and recover good visual acuity, the
severe variants of CSCR are less likely to resolve
with one study showing only 52% of eyes regain-
ing 6/6 vision.
2
The cause of CSCR is unknown and the
majority are considered to be idiopathic.
3
However, several studies have shown an associ-
ation between corticosteroid use and CSCR.
1–4
Multiple routes of steroid administration have
been implicated including oral, intravenous,
inhaled, intranasal, epidural and intra-articular
forms.
5 The underlying pathogenesis of CSCR sec-
ondary to steroid therapy has been attributed to
disruption of the blood retinal barrier, hyperper-
meability of the choriocapillaris and damage to
the retinal pigment epithelial pump.
1
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1Figure 1
Showing the OCT, fundus autoﬂuorescence and angiographic ﬁndings in the right and left eyes at pres-
entation. A and B: OCT images captured on the Topcon 3D OCT 1000. No subretinal ﬂuid seen in the right
eye (1A). Left eye shows disruption of the retinal pigment epithelium associated with shallow subretinal
ﬂuid localized to the superotemporal macular area (red arrow) (1B). C and D: Fundus autoﬂuorescence
images captured on the Heidelberg retina angiograph 2 (HRA 2). There is an area of mottled reduced
autoﬂuorescence with bright margins, a gravitational distribution and extensive foveal involvement in
the right eye (1C). The left eye shows a localized and relatively uniform area of increased autoﬂuores-
cence, sparing the macula (1D). E and F: Fundus ﬂuorescein angiogram images captured on HRA 2. There
is mottled hyperﬂuorescence in the right eye at 1 minute corresponding to the area of abnormal fundus
autoﬂuorescence (1E). The left eye at 45 seconds shows a triangular area of hypoﬂuorescence (corre-
sponding to a similar shaped area of increased fundus autoﬂuorescence) surrounded by mottled hyper-
ﬂuorescence(1F). Neithereye showed anyareaof focal hyperﬂuorescenceorchoroidalneovascularization
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Balini
BalasubramaniamThere are several published reports describing
the development of CSCR in renal transplant
patients.
6,7 This case is challenging because when
the patient ﬁrst presented to the eye clinic, he had
already developed irreversible sight loss in one
eye and had an active sight-threatening disease in
the other. The immune suppression with low
dose prednisolone, however, was considered
necessary to prevent renal graft failure. The
patient had to make a difﬁcult decision between
continuing the steroids and risk losing his sight
entirely, or reducing his steroids and risking loss
of the transplant. After careful consideration he
chose to try to preserve his vision and reduce the
steroids asfaras possible,knowingthat ifthe trans-
plant were to fail he could revert to haemodialysis
to replace his renal function.
Management of idiopathic CSCR is reassurance
and observation unless it develops into chronic
or recurrent disease. Second-line treatment may
include photodynamic therapy, anti-vascularendo-
thelial growth factors (anti- VEGF) or non-visible
subthreshold micropulse diode laser.
8,9 Verteporﬁn
photodynamic therapy has shown promising
results but complications such as choroid neovasu-
clarization and damage to the choroidal circulation
are limitations to its use.
9,10 A recent prospective
trial using low ﬂuence rate photodynamic therapy
demonstrated improved subretinal ﬂuid and
visual acuity while inducing less damage to the
choroidal circulation than normal ﬂuence photody-
namic therapy, however, this study excluded
patients who were taking corticosteriods.
10 Intra-
vitreal anti-VEGF agents have also been used in
the management of chronic CSCR and a recent
study suggests it may be an alternative treatment
option.
11 Non-visible subthreshold micropulse
diode laser has shown promising results in
smaller studies with short-term follow-up.
9
For CSCR secondary to steroid use, however,
the ﬁrst line of management would be to remove
the underlying cause by taking the patient off
the drug. The important management issues to
consider in this case would be: (1) the morbidity
of renal graft failure versus the possibility of
bilateral and irreversible loss of vision; (2)
whether a reduced steroid dose would be sufﬁ-
cient to halt the disease as opposed to complete
withdrawal; and (3) the effectiveness of second-
line ophthalmic treatments for CSCR if the
patient remained on low-dose prednisolone.
Close liaisons with the treating renal physician
and active patient involvement in the decision-
making processes are the key to managing this
complex case.
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